Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: a systematic review and meta‐analysis
P Sarma, H Kaur, H Kumar, D Mahendru… - Journal of medical …, 2020 - Wiley Online Library
Following the demonstration of the efficacy of hydroxychloroquine against severe acute
respiratory syndrome coronavirus 2 in vitro, many trials started to evaluate its efficacy in …
respiratory syndrome coronavirus 2 in vitro, many trials started to evaluate its efficacy in …
Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19
An outbreak of novel coronavirus-related pneumonia COVID-19, that was identified in
December 2019, has expanded rapidly, with cases now confirmed in more than 211 …
December 2019, has expanded rapidly, with cases now confirmed in more than 211 …
In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)
P Sarma, N Shekhar, M Prajapat, P Avti… - Journal of …, 2021 - Taylor & Francis
The N terminal domain (NTD) of Nucleocapsid protein (N protein) of coronavirus (CoV)
binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex …
binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex …
Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: a molecular docking study
SARS-CoV-2 is the pathogen agent of the new corona virus disease that appeared at the
end of 2019 in China. There is, currently, no effective treatment against COVID-19. We report …
end of 2019 in China. There is, currently, no effective treatment against COVID-19. We report …
COVID-19 and vaccination: myths vs science
Introduction Several vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) have been developed since the inception of the coronavirus disease 2019 …
(SARS-CoV-2) have been developed since the inception of the coronavirus disease 2019 …
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
Background The receptor binding domain (RBD) of spike protein S1 domain SARS-CoV-2
plays a key role in the interaction with ACE2, which leads to subsequent S2 domain …
plays a key role in the interaction with ACE2, which leads to subsequent S2 domain …
Pharmacological treatments of COVID-19
The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19),
which was reported for the first time in December 2019, was named by the World Health …
which was reported for the first time in December 2019, was named by the World Health …
COVID-19 pandemic: A review based on current evidence
VM Mahalmani, D Mahendru, A Semwal… - Indian journal of …, 2020 - journals.lww.com
In December 2019, severe acute respiratory syndrome-coronavirus-2, a novel coronavirus,
initiated an outbreak of pneumonia from Wuhan in China, which rapidly spread worldwide …
initiated an outbreak of pneumonia from Wuhan in China, which rapidly spread worldwide …
Current treatments and therapeutic options for COVID-19 patients: a systematic review
E Mehraeen, Z Najafi, B Hayati… - … Current Drug Targets …, 2022 - ingentaconnect.com
Introduction: COVID-19 is the third rising epidemic in the 21st century that quickly turned into
a worldwide pandemic. Many clinical studies have been achieved to investigate treatments …
a worldwide pandemic. Many clinical studies have been achieved to investigate treatments …
COVID-19–associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis
A Bhattacharyya, P Sarma, H Kaur… - Indian Journal of …, 2021 - journals.lww.com
BACKGROUND: Till now, no meta-analysis is available to address the clinical profile, risk
factors, different interventions, and outcomes among COVID-19–associated rhino-orbito …
factors, different interventions, and outcomes among COVID-19–associated rhino-orbito …